Derivation of the human embryonic stem cell line RCe006-A (RC-2)  by De Sousa, P.A. et al.
Stem Cell Research 16 (2016) 452–455
Contents lists available at ScienceDirect
Stem Cell Research
j ourna l homepage: www.e lsev ie r .com/ locate /scrLab Resource: Stem Cell LineDerivation of the human embryonic stem cell line RCe006-A (RC-2)P.A. De Sousa a,b,c,⁎, B. Tye a, K. Bruce a, P. Dand a, G. Russell a, J. Gardner a, J.M. Downie a,
M. Bateman a, A. Courtney a
a Roslin Cells Limited, Nine Edinburgh Bio-Quarter, 9 Little France Road, Edinburgh EH16 4UX, UK
b Centre for Clinical Brain Sciences, University of Edinburgh, UK
c MRC Centre for Regenerative Medicine, University of Edinburgh, UKN
A
In
P
C
D
T
S
O
K
A
Li
In
E
⁎ Corresponding author at: University of Edinburg
Edinburgh Bio-Quarter, 9 Little France Road, Edinburgh EH
E-mail addresses: paul.desousa@ed.ac.uk, Paul.desousa
http://dx.doi.org/10.1016/j.scr.2016.02.029
1873-5061/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 9 February 2016
Accepted 11 February 2016
Available online 16 February 2016The human embryonic stem cell line RCe006-A (RC-2) was derived from a frozen and thawed blastocyst volun-
tarily donated as surplus to fertility requirements following ethics committee approved informed consent under
licence from the UKHuman Fertilisation and Embryology Authority. The cell line exhibits expression of expected
pluripotency markers and in vitro differentiation potential to three germinal lineage representative cell popula-
tions. It has a male trisomy 12 karyotype (47XY, +12). Microsatellite DNA marker identity and HLA and blood
group typing data are available.
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RCe006-A (RC-2) was derived from a frozen and thawed, surplus
to requirement, blastocyst. The cell line was derived by whole em-
bryo outgrowth on mitotically inactivated human dermal ﬁbroblast
(HDF) feeder cells using HDF conditioned medium and expanded
under feeder free conditions.
RCe006-A (RC-2) was shown to be pluripotent by expression
of the pluripotency markers Oct4, Nanog Tra-1-60 and Tra-1-81,
but not the differentiation marker SSEA-1 using immunocyto-
chemistry (Table 1, Fig. 1). By ﬂow cytometric analysis, expres-
sion of the pluripotency makers SSEA-4, Tra-1-60 and Tra-1-81
was 81.8%, 55.0% and 43.6%, respectively, whereas low expression
of the differentiation marker SSEA-1 (2.3%), was observed at
passage 6 (Fig. 2). Differentiation to the three germ layers, endo-
derm, ectoderm and mesoderm, was demonstrated using embry-
oid body formation with all three germ layers present as shown
by expression of α-fetoprotein, β-tubulin and muscle actin
(Fig. 3).
A microsatellite PCR proﬁle has been obtained for the cell line,
and HLA Class I and II typing is available (Table 2). Blood group
genotyping gave the blood group BO1 (Table 2).Veriﬁcation and authentication
The cell line was analysed for genome stability by G-banding
(Fig. 4) and showed an abnormal 47XY, +12 male genotype in all
20 cells analysed. The cell line is free from mycoplasma contamina-
tion as determined by RC-qPCR. Microsatellite PCR DNA proﬁling
for cell identity is available.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Summary of quality control testing and results for RCe006-A (RC-2).
Classiﬁcation Test Purpose Result
Donor screening HIV 1 + 2
Hepatitis B
Hepatitis C
Donor screening for adventitious agents Negative
Identity Microsatellite PCR (mPCR) DNA proﬁling to give cell line its signature, gender/species Performed
Phenotype Immunocytochemisty To assess levels of staining for pluripotency markers Expression of Oct4, Nanog,
Tra-1-60 and Tra-1-81
Flow cytometry Assess antigen levels & cell surface markers commonly
associated with hESC
Tra 1-60: 55.0%
Tra 1-81: 43.6%
SSEA-4: 81.8%
SSEA-1: 2.3%
Genotype
(details provided in Table 2)
Blood group genotyping
(DNA analysis)
To establish blood group of the line BO1
Karyology (G-Banding) Conﬁrmation of normal ploidy by G-banding 47XY, +12
HLA tissue typing To establish full HLA Type I and II genotype of the line HLA typed Class I and Class II
Microbiology and virology Mycoplasma Mycoplasma testing by RT-qPCR Negative
Endotoxin Screening for endotoxin levels 4.19 EU/ml
Morphology Photography To capture a visual record of the line Normal
Differentiation potential Embryoid body formation To show differentiation to three germ layers Expression of muscle actin,
β-tubulin and α-feto protein
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Ethics
Derivation of hESC from surplus to requirement and failed to
fertilise/develop embryos was approved by The Scotland A Research
Ethics Committee and local ethics board at participating fertility clinics
and conducted under licence no R0136 from the UK HFEA with in-
formed donor consent.
Cell culture
Frozen embryos were thawed using Embryo Thawing Pack (Origio
(Medicult), Denmark) using standard techniques and were cultured
EmbryoAssist (Origio) until Day 3 or BlastAssist (Origio) after Day 3 of
development. Embryos were cultured at 36.5–37.5 °C, 5 ± 0.5% CO2,
5 ± 0.5% O2 in drops under parafﬁn oil (Origio) and transferred to
fresh medium at least every 2–3 days.Fig. 1. Immunostaining of RCe006-A (RC-2) show expression of the pluripotency markers Oc
(green). Cell nuclei are counterstained with DAPI (blue).By Day 8 of development, or when spontaneous hatching occurred,
embryos were placed in derivation conditions consisting of mitotically
inactivated neonatal human dermal ﬁbroblasts (HDFs) (ThermoFisher
Scientiﬁc (Cascade Biologics), Paisley, UK) on tissue culture plastic pre-
coatedwith 2 μg/cm2 human laminin (Sigma-Aldrich, Dorset, UK) as per
manufacturer's recommendation. If required, assistedhatchingwasper-
formed by removing the zona pellucidae mechanically using Swemed
cutting tools (Vitrolife, Göteborg, Sweden).
HDF cells were cultured in DMEM (Lonza, Slough, UK), 10% FCS
(GE Healthcare (PAA), Buckinghamshire, UK) and 2 mM L-gluta-
mine (ThermoFisher Scientiﬁc). HDFs were mitotically inactivated
using gamma irradiation at 50 Gy using a Gammacell Elite 1000
machine. For use as a feeder layer, irradiated HDFs were plated
at 2–50,000 cells/cm2 in HDF conditioned medium (80% Knockout-
DMEM, 20% Knockout serum replacement (KOSR), 1 mM glutamine,
0.1 mM β-mercaptoethanol, 1% nonessential amino acids, and 4 ng/ml
human bFGF (all ThermoFisher Scientiﬁc) over 24 h intervals over
7 days) supplemented with an additional 24 ng/ml human bFGF. Cellst-4 (red), Nanog, Tra-1-60, Tra-1-81 (green), but not the differentiation marker SSEA-1
Fig. 2. RCe006-A (RC-2) (passage 6) was subjected to ﬂow cytometry analysis for markers of pluripotency with speciﬁc antibody or isotype control as indicated above the histograms.
Percentage staining is indicated in Table 1.
Fig. 3. In vitro embryoid body differentiation of RCe006-A (RC-2). Speciﬁc staining shown in green, from left to right: control, ectoderm (β-tubulin III), mesoderm (muscle actin), and
endoderm (α-fetoprotein). Cell nuclei are counterstained with DAPI (blue).
Table 2
Microsatellite PCR, blood group and HLA tissue typing results for RCe006-A (RC-2).
Microsatellite PCR results
D3S1358 1 D3S1358 2 vWA 1 vWA 2 D16S539 1 D16S539 2 D2S1338 1 D2S1338 2
15 15 17 18 9 11 20 22
Amelogenin 1 Amelogenin 2 D8S1179 1 D8S1179 2 D21S11 1 D21S11 2 D18S51 1 D18S51 2
X Y 12 14 29 30 12 15
D19S433 1 D19S433 2 THO1 1 THO1 2 FGA 1 FGA 2 CSF1PO 1 CSF1PO 2
12 14 7 9 Iw* Iw* 11 12
D5S818 1 D5S818 2 D7S820 1 D7S820 2 D13S317 1 D13S317 2 TPOX 1 TPOX 2
11 12 7 8.2 12 13 0** 0**
*Peak falls below threshold to conﬁdently score.
**No peak detected.
Blood group genotyping
RhD RhC Rhc RhE Rhe Fy a Fy b Fy GATA
pos pos neg neg pos pos pos neg
Jka Jkb K k M N S S
pos pos neg pos neg pos neg pos
Kp a Kp b Do a Do b ABO
neg pos pos? pos? BO1
HLA tissue typing
HLA Class I Type HLA-A*01, A*26; B*08, B*37; C*06, C*07
HLA Class II Type HLA-DRB1*03, DRB1*10; DRB3*02; DQB1*02, DQB1*05
Comment DRB1*03 is expressed serologically as a DR17
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Fig. 4. RCe006-A (RC-2) was analysed by Giesma staining of 20 metaphase spreads and showed an abnormal 47XY,+12 karyotype in all cells analysed.
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dium exchanged 6 days a week.
The established cell line was expanded and banked using CellStart
matrix and Stempro hESC Serum Free Medium (ThermoFisher Scientif-
ic). Passaging was performed mechanically using an EZ passage tool
(ThermoFisher Scientiﬁc). hESC lines were expanded to 25–30 wells of
a 6-well plate and cryopreserved in 0.5–1ml KOSR based cryopreserva-
tion solution (75% KO-DMEM, 15% Xeno-free KOSR (ThermoFisher Sci-
entiﬁc) and 10% DMSO (Origen Biomedical, Texas, USA)) or Cryostor
CS10 (Biolife Solution, Washington, USA).
Mycoplasma
Mycoplasma detection was performed using Applied Biosystems
PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit and MicroSEQ™
MycoplasmaReal-Time PCRDetection Kit (ThermoFisher Scientiﬁc (Ap-
plied Biosystems, ThermoFisher Scientiﬁc) according to the
manufacturer's instruction.
Endotoxin
Endotoxin levels were determined using the Kinetic-QCL assay
(Lonza) and an incubating plate reader (BioTek ELx808) according to
the manufacturer's instructions. Brieﬂy, an unknown sample was com-
pared with a standard curve of known levels of control endotoxin. An
assay was deemed valid if the coefﬁcient of correlation, r ≥ 0.980 and
the CV (%) for the standard curve was ≤10%.
Flow cytometry
Human embryonic stem cells were dissociated using Trypsin
(ThermoFisher Scientiﬁc). Non-speciﬁc staining was blocked using
5% goat serum (Sigma) in PBS (Lonza) containing 0.01% Tween-20
(Sigma). Cells were stained with antibodies against SSEA-4, SSEA-1,
Tra-1-60 and Tra-1-81 (all BD, Oxford, UK), at 250 ng per reaction
followed by Goat F(ab)2 anti-mouse IgM-PE Goat F(ab)2 anti-mouse
IgG3-FITC (1:200; Santa Cruz Biotechnology, Texas, USA). Cells were
analysed using a FACS Aria ﬂow cytometer (BD).
Immunocytochemistry
hESCs were ﬁxed in 4% paraformaldehyde (ThermoFisher Scientiﬁc
(Alfa Aesar)), permeabilised using 100% ethanol (ThermoFisher
Scientiﬁc) and stained with AFP (1:500; Sigma), β-tubulin III
(1:1000; Sigma), muscle-speciﬁc actin (1:50; DAKO, Glostrup,
Denmark), Oct-4 (1:200; Santa Cruz Biotechnology), Nanog (1:20;R&D Systems, Abingdon, UK), Tra-1-60, Tra-1-81, SSEA-1 (all 1:50;
BD) and secondary antibodies anti-mouse IgG-FITC (1:200; Sigma),
anti-mouse IgG-AlexaFluor 488, anti-goat IgG-AlexaFluor 488, anti-
goat IgG-AlexaFluor-594, anti-donkey polyclonal AlexaFluor-594
(all 1:200; ThermoFisher Scientiﬁc). Images were acquired using a
Zeiss S100 Axiovert ﬂuorescence microscope or Nikon eC1 confocal
microscope.
In vitro differentiation
hESC cells were pre-treated for 1 h with 10 μM ROCK inhibitor in
Stempro hESC SFM (ThermoFisher Scientiﬁc) and embryoid bodies
EBs generated in ultra low attachment plates (Corning) for 7 days before
being transferred into EBmedium (20% FBS (GE Healthcare (PAA)), 80%
KO-DMEM 1 mM L-glutamine, 0.1 mM β-mercaptoethanol, 1% nones-
sential amino acids (all ThermoFisher Scientiﬁc)), on glass slide tissue
culture chambers (Nunc, ThermoFisher Scientiﬁc) coated with 0.5% gel-
atin (Sigma) at 0.1 ml/cm2 for 14 days.
Genomic analysis
All outsourced assayswere carried out under aQuality and Technical
Agreement. DNA was extracted using the QIAamp DNA Mini kit
(Qiagen, Manchester, UK) according to the manufacturer's recommen-
dations and provided in recommended quantities to the service
providers.
Microsatellite PCR, or Short TandemRepeat analysis, was used to de-
termine cell line identity and was carried out by Public Health England.
A proﬁle was obtained for the following core alleles: vWA, D16S539,
Amelogenin, THO1, CSF1PO, D5S818, D75820, D135317 and TPOX.
Human Leukocyte Antigen (HLA) tissue typing was carried out by
the Scottish National Blood Transfusion Service.
Blood group genotyping was carried out by the Molecular Diagnos-
tics Laboratory at NHSBT.
Karyotype analysis was carried out by The Doctors Laboratory
(London, UK) or the Western General Cytogenetics Laboratory
(Edinburgh, UK). Live cells at 60–70% conﬂuency were shipped over-
night in warm containers, ﬁxed and analysed by standard G-banding
analysis. For research grade lines, 20 spreads were analysed.
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